医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare to Present Clinical Data of Orelabrutinib at the Upcoming 62nd Annual Meeting of ASH

2020年11月05日 PM10:28
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company will present latest clinical data of its BTK inhibitor Orelabrutinib at the 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, 2020, which will be held online. The study in Patients with Relapsed or Refractory Mantle Cell Lymphoma, led by Dr. Jun Zhu, and the study in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia, led by Dr. Jianyong Li, will be presented in three posters. This is the second consecutive year for InnoCare to present Orelabrutinib data at ASH.

Poster Presentation 1:

Title:Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Abstract Number:1140

Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I

Session Date: Saturday, December 5, 2020

Presentation Time: 7:00 AM-3:30 PM

Location: Poster Hall (Virtual Meeting)

Presenter: Yuqin Song, M.D., Ph.D.

Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper140172.html

Poster Presentation 2:

Title:Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Abstract Number:2048

Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II

Session Date: Sunday, December 6, 2020

Presentation Time: 7:00 AM-3:30 PM

Location: Poster Hall (Virtual Meeting)

Presenter: Yuqin Song, M.D., Ph.D.

Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper141781.html

Poster Presentation 3:

Title:Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Abstract Number:1320

Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I

Session Date: Saturday, December 5, 2020

Presentation Time: 7:00 AM-3:30 PM

Location: Poster Hall (Virtual Meeting)

Presenter: Wei Xu, M.D.

Abstract website: https://ash.confex.com/ash/2020/webprogram/Paper134531.html

InnoCare will release detailed Orelabrutinib clinical data during ASH meetings.

About Orelabrutinib

Orelabrutinib is a selective BTK inhibitor for the treatment of cancers and autoimmune diseases, which has been supported by the national special project for the development of major new drugs. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. Current clinical data have demonstrated orelabrutinib’s robust efficacy and safety profile. Orelabrutinib’s two indications have been included in priority review by the NMPA.

About InnoCare Pharma

InnoCare Pharma is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005636/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations

86-10-66609999

ir@innocarepharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Take ‘VOW’ to Protect All Humanity: ‘Vaccinate Our World!’
  • 太平洋電気通信協議会が第44回年次総会の参加募集を発表
  • アビオメッド、ImpellaのPROTECT IVランダム化対照試験に最初の患者を組み入れたことを発表
  • Prestige Biopharma’s New Vaccine Production Centre for Infectious Diseases Including COVID-19
  • Pacific Telecommunications Council Announces the Call for Participation for Its 44th Annual Conference